CINECA IRIS Institutional Research Information System

CREMOLINI, CHIARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 22.903
AS - Asia 13.386
EU - Europa 7.611
SA - Sud America 2.595
AF - Africa 576
OC - Oceania 31
Continente sconosciuto - Info sul continente non disponibili 11
Totale 47.113
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 22.295
SG - Singapore 4.420
CN - Cina 2.982
IT - Italia 2.696
HK - Hong Kong 2.463
BR - Brasile 2.083
VN - Vietnam 1.421
SE - Svezia 846
DE - Germania 738
BG - Bulgaria 632
GB - Regno Unito 547
FR - Francia 513
RU - Federazione Russa 374
CA - Canada 363
JP - Giappone 355
FI - Finlandia 349
IN - India 345
TR - Turchia 273
KR - Corea 189
AR - Argentina 184
BD - Bangladesh 178
AT - Austria 169
UA - Ucraina 158
CI - Costa d'Avorio 157
NL - Olanda 151
IQ - Iraq 128
ID - Indonesia 122
ZA - Sudafrica 105
MX - Messico 102
PL - Polonia 99
EC - Ecuador 67
PK - Pakistan 66
CH - Svizzera 64
SA - Arabia Saudita 64
UZ - Uzbekistan 62
VE - Venezuela 60
CO - Colombia 56
ES - Italia 55
SN - Senegal 55
NG - Nigeria 53
MA - Marocco 49
PY - Paraguay 45
PH - Filippine 37
CL - Cile 33
BE - Belgio 32
EG - Egitto 30
KE - Kenya 30
NP - Nepal 28
PE - Perù 28
UY - Uruguay 28
AE - Emirati Arabi Uniti 27
TN - Tunisia 27
IE - Irlanda 24
JM - Giamaica 24
CZ - Repubblica Ceca 23
MY - Malesia 23
OM - Oman 23
LT - Lituania 22
AU - Australia 21
HN - Honduras 17
JO - Giordania 17
CR - Costa Rica 16
TW - Taiwan 15
AZ - Azerbaigian 14
DZ - Algeria 14
ET - Etiopia 14
IL - Israele 14
PA - Panama 14
AL - Albania 13
PS - Palestinian Territory 13
DO - Repubblica Dominicana 12
KG - Kirghizistan 12
PT - Portogallo 12
TT - Trinidad e Tobago 12
BO - Bolivia 11
GR - Grecia 11
IR - Iran 11
NI - Nicaragua 11
RO - Romania 11
SY - Repubblica araba siriana 11
BB - Barbados 10
BJ - Benin 10
BY - Bielorussia 10
KZ - Kazakistan 10
LB - Libano 10
NZ - Nuova Zelanda 10
TH - Thailandia 10
KH - Cambogia 8
NO - Norvegia 8
LV - Lettonia 7
DK - Danimarca 6
EU - Europa 6
PR - Porto Rico 6
QA - Qatar 6
SV - El Salvador 6
AO - Angola 5
EE - Estonia 5
GE - Georgia 5
LU - Lussemburgo 5
MK - Macedonia 5
Totale 47.016
Salva come PNG Salva come JPEG
Città #
Hong Kong 2.413
Ashburn 2.399
Singapore 2.386
Woodbridge 1.995
Fairfield 1.614
San Jose 1.577
Ann Arbor 1.424
Santa Clara 1.335
Houston 1.298
Chandler 1.087
Dallas 1.080
Shanghai 760
Seattle 722
Sofia 628
Milan 604
Wilmington 594
Cambridge 586
New York 563
Beijing 520
Boardman 485
Ho Chi Minh City 406
Los Angeles 403
Tokyo 314
Hefei 308
Princeton 297
Lawrence 284
Lauterbourg 266
Hanoi 249
Medford 235
Ottawa 228
Florence 187
Pisa 182
Seoul 181
São Paulo 175
Council Bluffs 167
London 165
Abidjan 156
Dearborn 152
Des Moines 150
Jacksonville 142
Munich 137
Redondo Beach 137
Rome 133
Nanjing 129
Buffalo 128
Istanbul 122
Serra 121
Vienna 121
Frankfurt am Main 106
Düsseldorf 104
Helsinki 102
Dong Ket 97
Cascina 89
Warsaw 87
San Diego 85
Izmir 82
Columbus 80
Rio de Janeiro 76
Ogden 74
Chicago 69
Orem 67
Nuremberg 66
Turku 63
Bremen 60
Redwood City 60
Lancaster 59
Haiphong 56
Dakar 54
Genoa 52
Da Nang 50
Nanchang 50
Baghdad 49
Belo Horizonte 49
Lagos 49
Phoenix 49
Tashkent 49
Turin 47
Bern 46
Chennai 46
Lappeenranta 45
Johannesburg 43
Dhaka 42
Montreal 42
Kunming 41
Seacroft 41
Shenyang 40
Naples 39
Boulder 38
Mumbai 36
Brasília 34
Fuzhou 34
Jakarta 32
Guangzhou 31
Jüchen 31
Norwalk 31
Toronto 31
Hebei 30
Marseille 30
San Francisco 30
Atlanta 29
Totale 32.567
Salva come PNG Salva come JPEG
Nome #
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: Updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study 326
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer 277
EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan 243
TRIBE-2: A phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group 218
Comparison of digital PCR systems for the analysis of liquid biopsy samples of patients affected by lung and colorectal cancer 217
OUTCOME OF SECOND-LINE TREATMENT AFTER FIRST-LINE CHEMOTHERAPY WITH THE GONO FOLFOXIRI REGIMEN. 217
Homeobox B9 mediates resistance to anti-VEGF therapy in colorectal cancer patients 208
Zebrafish Patient-Derived Xenograft Model to Predict Treatment Outcomes of Colorectal Cancer Patients 202
DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients 202
Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: evaluation of the effects of switched schedules and related pharmacodynamics 192
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis 192
Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: Results from TRIBE and FIRE3 trials 191
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial 191
Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis 190
Analysis of PTEN expression and KRAS mutations on primaries (PRIM) and metastases (METS) to predict benefit from cetuximab plus irinotecan (CETIRI) in metastatic colorectal cancer (MCRC) patients (PTS) 189
Pten expression and Kras mutations as predictors of benefit from cetuximab plus irinotecan (CETIRI) in metastatic colorectal cancer (MCRC) patients (PTS) 189
KRAS and BRAF mutational analyses in a phase II trial of first-line FOLFOXIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts) 189
A prognostic model for use before elective surgery to estimate the risk of postoperative pulmonary complications (GSU-Pulmonary Score): a development and validation study in three international cohorts 186
KRAS codon 61, 146 and BRAF V600E mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer 185
Prevention and management of adverse events related to regorafenib 185
TAS-102 for the treatment of metastatic colorectal cancer 184
Pattern of recurrence and survival after D2 right colectomy for cancer: is there place for a routine more extended lymphadenectomy? 183
Exploratory analysis of circulating pro-and anti-angiogenic factors in metastatic colorectal cancer (MCRC) patients, treated with GONO-folfoxiri plus bevacizumab (BV) 182
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab 181
Circulating amphiregulin (AR) plasma levels as surrogate pharmacodynamic markers of EGFR inhibition with cetuximab in metastatic colorectal cancer (MCRC) patients 179
Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer 178
DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer 178
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer 178
Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial 178
Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO 177
Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials 175
BRAF V600E mutation and Amphiregulin (AR) immunohistochemical expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (mCRC) patients 175
ALK, ROS1, and NTRK rearrangements in metastatic colorectal cancer 175
Association of BRAF mutations and EGFR Intron-1 L/L genotype with resistance to cetuximab plus irinotecan treatment in KRAS wild-type metastatic colorectal cancer patients 174
Circulating tumor DNA analysis in colorectal cancer: From dream to reality 174
BRAF V600E mutation and amphiregulin (AR) immunohistochemical expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (mCRC) patients 173
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer 173
EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle 173
Quantitative evidence for early metastatic seeding in colorectal cancer 173
Exploratory analysis of circulating pro-and anti-angiogenic factors in metastatic colorectal cancer (MCRC) patients, treated with GONO-folfoxiri plus bevacizumab (BV) 172
Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer 171
BRAF V600E mutation and amphiregulin (AR) immunohistochemical expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (MCRC) patients 170
FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus beva s first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trial. 170
Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials 170
Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable 170
Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab. 169
Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients 169
Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials 168
Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib 168
Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases 167
Host genetic variants in the Insulin Growth Factor Binding Protein-3 impact on servival of patients with advanced gastric cancer treated with palliative chemotharapy 167
Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: A clinical and molecular proof of concept study 167
Immune Profiling of Deficient Mismatch Repair Colorectal Cancer Tumor Microenvironment Reveals Different Levels of Immune System Activation 167
The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients 167
VEGF gene polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts) 166
Case-report: folfoxiri plus bevacizumab in "poor-risk" liver-only metastatic colorectal cancer: case report and state-of-the-art. 166
Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component 166
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials 165
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study 165
VEGF gene polymorphisms in the prediction of benefit from first-line folfiri plus bevacizumab (BV) in metastatic colorectal cancer (MCRC) patients (pts) 165
Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer 165
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: Final results of the randomized BEBYP trial 165
Targeting vascular endothelial growth factor pathway in first-line treatment of metastatic colorectal cancer: state-of-the-art and future perspectives in clinical and molecular selection of patients 164
Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3 164
KRAS and BRAF mutational analyses in a phase II trial of first-line folfoxiri plus bevacizumab (BV) in metastatic colorectal cancer (MCRC) patients (pts) 163
Circulating angiogenic factors as predictors of benefit from bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Translational analyses from the phase III BEBYP trial. 163
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial 163
Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients 163
Analysis of NRAS mutation as poor prognostic indicator and predictor of resistance to anti-EGFR monoclonal antibodies (anti-EGFRs) in metastatic colorectal cancer (mCRC) patients (pts). 162
Location of primary tumor and benefit from anti-epidermal growth factorreceptor monoclonalantibodies in patients with RAS and BRAF wild-typemetastatic colorectal cancer 162
The landscape of alterations in DNA damage response pathways in colorectal cancer 162
Cytotoxic triplets plus a biologic: state-of-the-art in maximizing the potential of up-front medical treatment of metastatic colorectal cancer 160
A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer 160
High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice 159
TRIPLETE: A randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer 159
Primary Tumor Sidedness and Benefit from FOLFOXIRI plus Bevacizumab as Initial Therapy for Metastatic Colorectal Cancer 159
First-line therapy for mCRC-the influence of primary tumour location on the therapeutic algorithm 158
Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer 158
Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib 158
KRAS and BRAF genotyping of synchronous colorectal carcinomas. 157
Pharmacological effects of the simultaneous and sequential combinations of trifluridine/tipiracil (TAS-102) and 5-fluorouracil in fluoropyrimidine-sensitive colon cancer cells 157
Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO 156
BRAF-mutated metastatic colorectal cancer between past and future 155
FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). 154
High activity and resection rate in molecularly selected patients with unresectable metastatic colorectal cancer (MCRC) treated with panitumumab (P) and folfoxiri as first-line therapy : a phase II study. 154
Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial. 153
RET fusions in a small subset of advanced colorectal cancers at risk of being neglected 152
Prognostic impact of ATM mutations in patients with metastatic colorectal cancer 152
AtezoTRIBE: A randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer 152
AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3 152
Second-line chemotherapy (CT) with or without bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts) who progressed to a first-line treatment containing BV: Updated results of the phase III “BEBYP”trial by the Gruppo Oncologico Nord Ovest (GONO). 151
CK7 and consensus molecular subtypes as major prognosticators in V600E BRAF mutated metastatic colorectal cancer 151
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer 149
Prospective analysis of the early modulation of plasma amphiregulin (AR) during treatment with cetuximab and irinotecan in irinotecan-refractory metastatic colorectal cancer (mCRC) patients (pts). 149
Prognostic significance of KRAS mutation rate in metastatic colorectal cancer patients. 149
Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients 149
Risk for developing brain metastases from colorectal cancer in long-term survivors with lung metastases and KRAS mutations. 148
A still missing piece of the FIRE-3 puzzle 148
Prevention of capecitabine toxicity using a 5-FU test dose 148
Surgery combined with intra-operative microwaves ablation for the management of colorectal cancer liver metastasis: A case-matched analysis and evaluation of recurrences 147
Totale 17.327
Salva come PNG Salva come JPEG
Categoria #
all - tutte 146.922
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 146.922
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021442 0 0 0 0 0 0 0 0 0 0 0 442
2021/20222.601 36 91 40 73 464 478 52 82 184 172 162 767
2022/20233.384 450 433 219 330 336 418 43 210 597 34 281 33
2023/20243.584 291 330 509 233 474 516 264 97 177 134 202 357
2024/202511.511 167 400 171 461 900 1.197 932 581 1.192 1.427 1.247 2.836
2025/202614.996 841 1.659 1.675 1.735 1.383 1.248 1.899 902 1.024 1.444 841 345
Totale 48.077